Better from the diet (nuts, vegetable oils).
⏱ 4 min read
Vitamin E is a family of eight related fat-soluble molecules: four tocopherols (alpha, beta, gamma, delta) and four tocotrienols (alpha, beta, gamma, delta), with partially shared and partially distinct biological profiles; the form historically most studied and marketed as a supplement is alpha-tocopherol, considered for decades the "active vitamin E" par excellence, although more recent data have revalued the role of gamma-tocopherol and tocotrienols, especially for specific cardiovascular and anti-inflammatory indications, an important nuance for understanding the real clinical profile of vitamin E as a supplement.
The classical biological function of vitamin E is that of a fat-soluble antioxidant: it is incorporated into cell membranes and plasma lipoproteins (especially LDL), where it protects polyunsaturated fatty acids from peroxidation, a function carried out in synergy with other antioxidants (vitamin C, glutathione, selenium); this antioxidant role was the basis of the great clinical expectations for vitamin E as a preventive supplement for cardiovascular disease and cancer in the 1980s and 1990s, expectations that large interventional clinical trials have considerably tempered with disappointing results for most population-level indications.
One of the most instructive clinical experiences in interventional nutrition is the vitamin E paradox: epidemiological data consistently associate high dietary intakes of vitamin E with lower cardiovascular risk, whereas the large clinical intervention trials with high-dose supplements (HOPE, GISSI-Prevenzione, ATBC, others) have been neutral or even slightly unfavorable; possible explanations include that the population-level effect is due to other components of foods rich in vitamin E (unrefined vegetable oils, nuts, seeds), that high supplement doses may be pro-oxidant in some contexts, or that isolated alpha-tocopherol may paradoxically displace gamma-tocopherol with less favorable net effects.
Despite the disappointing results in population-level cardiovascular prevention, vitamin E has specific indications with reasonable support: in nonalcoholic fatty liver disease (NASH), vitamin E at 800 IU/day for 96 weeks showed significant improvements in liver histology in the PIVENS trial, an indication supported in hepatology guidelines; in age-related macular degeneration as a component of the AREDS/AREDS2 cocktail, along with other specific nutrients; in cyclic mastalgia with some modest support.
More concerning, large meta-analyses (Miller et al. 2005, Bjelakovic et al. 2007) suggested associations between high-dose vitamin E supplementation (more than 400 IU/day) and a modest increase in all-cause mortality in some contexts, findings that, together with the lack of cardiovascular benefits, have led to a significant change in clinical practice: high doses of vitamin E without a specific clinical indication are no longer recommended; modern multivitamins contain significantly lower doses than those popular in the 1990s.
Nutritional doses are 15 mg of alpha-tocopherol equivalents (22 IU of natural vitamin E) daily in adults; for specific indications with clinical support (NASH, AREDS), doses adjusted according to protocol (typically 400-800 IU/day); the tolerable upper limit is 1,000 mg/day of alpha-tocopherol; the most common commercial forms are d-alpha-tocopherol (natural form, bioavailable) vs. dl-alpha-tocopherol (synthetic form, racemic mixture, lower bioavailability); "mixed tocopherols" formulations (a mixture of natural tocopherols) are theoretically more complete but specific clinical data are limited; the main dietary sources are unrefined vegetable oils (sunflower, olive, wheat germ), nuts (especially almonds and hazelnuts), seeds, avocado, and leafy green vegetables.
Generally well tolerated at nutritional and moderate doses; the adverse effects described at high doses are rare but potentially relevant: increased bleeding risk due to an antiplatelet effect (especially with doses above 400 IU/day combined with anticoagulants, antiplatelet agents, or low vitamin K); fatigue, headache, and occasional digestive discomfort; the increased risk of hemorrhagic stroke documented in some studies (with a simultaneous reduction in ischemic stroke, a neutral or questionable net result); people taking warfarin or antiplatelet agents should use caution with high doses; people who are going to undergo surgery should stop vitamin E at least 1-2 weeks beforehand; very high doses in people with cancer undergoing treatment may interfere with the efficacy of some chemotherapies or radiotherapies (consult with oncology); in pregnancy and breastfeeding, nutritional doses are safe, while therapeutic doses require supervision; the reasonable current clinical stance is: adequate vitamin E intake through the diet is important and favorable; specific high-dose supplementation should be reserved for clinical indications with support (NASH, AREDS) and not used routinely for general cardiovascular or cancer prevention.
Information, not medical advice. Scientific evidence reflects the quality of the studies.